Moderna’s Early Data Gives Big Boost For COVID-19 Vaccine Hopes
Sends Share Price Soaring Again
First eight volunteers produced antibodies which match or surpass those seen in patients who have recovered from COVID-19 – but big test awaits in Phase III.
You may also be interested in...
Pharma will oppose a patent pool, but the world still needs a way to guarantee fair access to COVID-19 vaccines.
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.
Vaccine manufacturing capacity has been lost in the UK in recent decades. Now a new Vaccines Manufacturing Innovation Centre will re-seed that capacity and expertise - and the pandemic is accelerating its arrival.